Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Deoleo Has Agreed to be Acquired by Acesur and Dcoop

    William Blair acted as the exclusive financial advisor to Deoleo Holding, S.L., a portfolio company of CVC Capital Partners and Alchemy Partners, in connection with its pending sale to a consortium comprising Acesur and Dcoop.

    Read more

  • Economics Weekly: Is the QRA Becoming the Treasury’s Equivalent of an FOMC Meeting?

    With no small supply of ink having already been spilt on the midterms, in this Economics Weekly, Richard de Chazal focuses on the news from the QRA, which is increasingly becoming the Treasury’s equivalent of an FOMC meeting—an event where subtle changes in language and policy settings can materially affect yields, liquidity, and financial conditions.

    Read more

  • What LPs Think About Continuation Vehicles

    A new William Blair survey finds LPs support the liquidity optionality provided by continuation vehicles (“CVs”) by a margin of roughly two to one. While opinion is still divided, the debate has largely moved from whether CVs should be used, to how general partners should approach using them.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures